Search online for non-surgical chin augmentation, and clinic menus often promote Juvéderm, Restylane, Volux, Kybella, and chin implants as if they were interchangeable. "Chin filler" is sold as a one-syringe profile fix. The FDA Premarket Approval (PMA) records, pivotal-trial volumes, and lower-face anatomy say otherwise.
Four facts should sit above the fold:
- Three hyaluronic-acid (HA) gels currently hold US PMA chin-profile indications for adults over the age of 21: Juvéderm Voluma XC (P110033/S047, 12 June 2020), Restylane Defyne (P140029/S027, 29 January 2021), and Restylane Lyft with Lidocaine (P040024/S142, 4 November 2025).
- Juvéderm Volux XC is approved for jawline definition, not chin retrusion. Using it on the chin is off-label relative to the PMA statement, even though some injectors choose it for firmness.
- Pivotal trials used more than one 1.0 mL syringe. Voluma's chin SSED reports median volumes of 2.0–2.5 mL by Fitzpatrick group; Defyne's median initial-plus-touch-up volume was 3.58 mL; Lyft's mean total was 3.39 mL.
- Filler, implant, Kybella, and mentalis toxin treat four different problems. Filler adds modest projection you can reverse; an implant is the structural answer for large sagittal deficiency; Kybella treats submental fat; pebble-chin texture is a mentalis problem.
This page is the US indication-and-routing map those four tools do not share.
Which chin fillers are FDA-approved in the United States right now?
In the United States, three HA fillers currently carry PMA approval specifically for chin-profile augmentation in adults over the age of 21:
- Juvéderm Voluma XC (Allergan / AbbVie) — PMA supplement P110033/S047, decision 12 June 2020. Deep (subcutaneous and/or supraperiosteal) injection for augmentation of the chin region to improve the chin profile. Supporting trial: NCT02833077, completed 11 October 2018.
- Restylane Defyne (Galderma) — PMA supplement P140029/S027, decision 29 January 2021. Deep (subcutaneous and/or supraperiosteal) injection for mild-to-moderate chin retrusion. Supporting trial: NCT03624816, completed 20 February 2020.
- Restylane Lyft with Lidocaine (Galderma) — PMA supplement P040024/S142, decision 4 November 2025. Subcutaneous and/or supraperiosteal implantation for mild-to-moderate chin retrusion. Supporting trial NCT05777759 (Lyft versus Voluma XC comparator), completed 10 July 2024.
| Product | Manufacturer | PMA | Decision date | Labeled chin use |
|---|---|---|---|---|
| Juvéderm Voluma XC (20 mg/mL HA) | Allergan / AbbVie | P110033/S047 | 12 June 2020 | Deep injection to improve the chin profile in adults over 21 |
| Restylane Defyne (20 mg/mL HA) | Galderma | P140029/S027 | 29 January 2021 | Mild-to-moderate chin retrusion in patients over 21 |
| Restylane Lyft with Lidocaine (20 mg/mL HA) | Galderma | P040024/S142 | 4 November 2025 | Mild-to-moderate chin retrusion in patients over 21 |
| Juvéderm Volux XC (25 mg/mL HA) | Allergan / AbbVie | P110033/S065 | 29 July 2022 | Jawline definition, not a chin-retrusion PMA |
| Restylane Shaype (NASHA HD) | Galderma | No US PMA | EU MDR 11 August 2026; prior Canada / Brazil | Not FDA-approved as of 22 August 2026 |
Filler can project soft tissue over a modest bony deficit. It does not remove neck fat, stop mentalis dimpling, or replace major surgical bone advancement.
Is Volux a chin filler, or a jawline filler?
Clinic copy often calls Volux XC "the newest chin and jawline filler." The PMA does not.
On 29 July 2022, FDA approved Juvéderm Volux XC under P110033/S065 for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate-to-severe loss of jawline definition (NCT03712137). That is a mandibular-border indication, not a chin-retrusion indication.
Volux is the firmest Vycross gel (25 mg/mL HA). Experienced injectors do place it on the mandibular symphysis off-label when they want a sharp anterior edge. That practice exists; it is still off-label. Allergan's dedicated chin-indication product is Voluma XC.
The family-level crosslinking map lives on Juvéderm vs Restylane. That post's one-line chin row historically listed Volux alongside Voluma; the PMA table on this page is the correction.
What about Restylane Shaype?
Restylane Shaype is Galderma's NASHA HD (high-density) chin gel, marketed as bone-mimicking for deep, on-bone projection.
- Outside the US: Canada and Brazil already had clearances. Galderma announced European Union MDR approval for temporary chin-region augmentation on 11 August 2026.
- United States: As of 22 August 2026, no matching US PMA was located. Shaype cannot be sold or administered as an FDA-approved chin filler in US clinics until that review is complete.
Social posts about "bone-mimicking Shaype" are describing a product that is not on the US PMA list yet.
How long does chin filler last, and how much volume did the trials actually use?
"One syringe, one and done" is marketing. The SSEDs and the FDA consumer Defyne page report the volumes and responder rates below.
| Metric | Juvéderm Voluma XC (NCT02833077) | Restylane Defyne (NCT03624816) | Restylane Lyft (NCT05777759) |
|---|---|---|---|
| PMA | P110033/S047 | P140029/S027 | P040024/S142 |
| Design | Randomized, evaluator-blinded, no-treatment control | Randomized, evaluator-blinded, no-treatment control | Randomized, evaluator-blinded, active comparator vs Voluma XC |
| Primary endpoint | 2D Allergan Chin Retrusion Scale (ACRS) at 6 months | Galderma Chin Retrusion Scale (GCRS) at 12 weeks | Blinded-evaluator GCRS change at 3 months after last treatment |
| Trial volume | Median 2.0 mL (FST I/II), 2.5 mL (III/IV), 2.0 mL (V/VI); females 2.0 mL, males 3.7 mL | Median 3.58 mL initial + touch-up (range 1.0–6.0 mL); Week-48 retreatment median 2.00 mL | Mean 3.39 mL initial + touch-up (range 1.00–4.00 mL) |
| Primary result | 56.3% 2D ACRS responders in treatment; 28.8 percentage-point advantage over control at Month 6 (p = 0.0019) | FDA recently-approved page: 86.1% improved at 12 weeks; 73.7% at 48 weeks | Non-inferiority to Voluma XC demonstrated (mean GCRS change −0.94 vs −1.02; CI entirely below the 0.5 non-inferiority margin). Lyft GCRS responders: 83.6% at Month 3, 69.7% at Month 12 |
| Labeled duration (chin) | Up to 1 year | Up to 1 year | Up to 1 year |
| Common local reactions | SSED: injection-site responses in most treated subjects after initial treatment (93.8% in the FST I/II safety cell; 80.0% in the paired cell) | Tenderness, swelling, bruising, firmness (typically days, not months) | Swelling, firmness, bruising, pain |
Those milliliter figures are trial totals, not a prescription. HA syringes are sold as 1.0 mL units, so a "one-syringe chin" is usually under-correction relative to the volumes that supported approval. Ask for a plan in milliliters and a touch-up policy, not a slogan price for one syringe.
The Fitzpatrick V/VI finding on Voluma chin
The Voluma chin SSED (P110033/S047B) is explicit about darker phototypes. In Fitzpatrick V/VI, the primary 2D ACRS endpoint was not met at 6 months: 28.6% (4/14) responders in treatment versus 50.0% (3/6) in the no-treatment control. The same SSED notes that the primary endpoint was also below 50% in older subjects (≥51.5 years) and in males, while satisfaction rates were high and secondary endpoints were met in those subgroups. Investigator and subject GAIS responder rates in FST V/VI remained high (92.3% and 78.6%).
That is a labeled subgroup miss on a 2D photographic scale with a small V/VI N, not a finding that Voluma is unsafe on darker skin. It is a reason to choose an injector who evaluates chin projection on your bone structure and phototype, and who does not treat a 2D trial photograph as a promise.
Defyne and Lyft on the chin
Defyne is XpresHAn (flexible plus structural). Lyft is NASHA (high-G′, particulate, typically placed on bone). For the cheek head-to-head, see Restylane Lyft vs Voluma. Lyft's chin PMA is newer than that cheek article; chin volumes and the Voluma comparator live here.
Chin filler vs implant vs Kybella vs pebble-chin toxin
The usual error is using one syringe to treat four layers: bone, muscle, fat, and skin texture.
| Problem | What you actually have | First-line tool | What filler will not do |
|---|---|---|---|
| Mild-to-moderate retrusion | Short chin on profile; labeled Defyne/Lyft language | On-label HA (Voluma, Defyne, or Lyft) | Permanent bone change |
| Large sagittal deficiency | Severe microgenia; filler would look doughy ("witch's chin") | Silicone or porous implant, or sliding genioplasty | Reverse a large bony deficit without unnatural volume |
| Submental fullness | Fat pad, not a short chin | Kybella vs chin liposuction | Dissolve fat |
| Pebble / orange-peel chin | Hyperactive mentalis | Pebble-chin mentalis toxin | Smooth a contracting muscle; filler on an overactive mentalis often looks lumpier |
HA filler is the reversible option for modest retrusion: immediate change, little downtime, dissolvable if the aesthetic result is wrong or a vascular event is recognized in time. Trade-off: maintenance. Repeat treatments over several years can cost more than a one-time implant.
Implant or genioplasty is the structural answer when the deficit is large enough that gel would migrate or look soft. Risks include infection, mental-nerve paresthesia, and long-term bone resorption — covered on chin implant complications and bone resorption.
Kybella (deoxycholic acid) or submental liposuction treats pre-platysmal fat. Filling a weak profile that is actually a fat pad makes a heavier lower face.
Mentalis toxin treats dimpling when you talk or at rest. Units belong on the pebble-chin page, not as a universal chin-filler recipe.
Male patients seeking gonial width and mandibular angle, rather than anterior projection, need a different vector: jawline filler for men.
Why can a modest chin injection still cause a vascular event?
Chin filler is not "safe because it is reversible." The mental artery exits the mental foramen (typically below the second premolar) and anastomoses with submental and inferior labial branches. PMC10296042 reviews that anatomy and the published occlusion cases. Intravascular HA can cause blanching, livedo, disproportionate pain, and tissue necrosis.
Deep supraperiosteal placement on bone, or a blunt cannula in the subcutaneous plane, is how injectors stay below the arterial arcade. Intermediate muscular planes are where those vessels run.
HA's advantage over calcium hydroxylapatite or PLLA is hyaluronidase: the gel can be dissolved if an occlusion is recognized quickly. That advantage is incomplete. Enzyme only helps if the clinic has unexpired hyaluronidase on site and the injector treats the event as an emergency. Ask, before you lie down, whether hyaluronidase is in the room — not in a locked cabinet off-site. This page does not publish a crash-cart recipe; the labeled warning and a credentialed injector's protocol do.
What should chin filler cost, and what is a low-price red flag?
There is no honest single US average. Cash-pay listings vary by city, injector credentials, and whether the quote is per 1.0 mL syringe or for a "chin package."
Price the plan, not the slogan:
- Multiply the clinic's per-syringe cash price by the milliliters actually proposed. Trial totals clustered around 2–4 mL, not 1 mL.
- Ask whether touch-up is included, and at what volume.
- Compare that multi-year maintenance math with a surgical implant quote if your deficit is large. The implant is not "more expensive" in every anatomy once you stop counting one syringe.
Red flags that are about safety, not bargaining:
- A chin quote that only makes sense for 0.5–1.0 mL when you want visible sagittal change.
- A price so far below local HA cash-pay norms that the product may be gray-market or split.
- No hyaluronidase on the premises.
- No named, on-label product (Voluma, Defyne, or Lyft) on the consent.
Frequently asked questions
How long will chin fillers last?
Chin labels for Voluma XC, Defyne, and Lyft describe duration up to 1 year. Cheek duration ("up to 2 years" for Voluma) is a different indication and should not be quoted for the chin. Some patients still see projection beyond 12 months because the chin is a low-shear, bone-supported site; that is practice, not a labeled guarantee.
Is chin filler worth the money?
For labeled mild-to-moderate retrusion, if you want reversibility and no operating room, yes — provided you budget for trial-like volumes and maintenance. If you need several milliliters every year, ask for an implant consult; the 5-year cash comparison often favors surgery for large deficits.
What type of filler is best for the chin?
High-G′, cohesive HA on bone. The three US chin-PMA options are Voluma XC, Defyne, and Lyft. Soft lip gels (Ultra, Silk) are the wrong rheology for pogonion projection.
How painful is chin filler?
The three chin-approved gels contain lidocaine. Deep on-bone placement is a pressure ache more than a superficial sting. Expect firmness for several days. Pain that is severe, immediate, and out of proportion to the poke is a vascular-warning symptom, not "normal soreness."
Can chin filler replace an implant?
Only for modest projection. It cannot lengthen a severely short mandible or replace osteotomy.
Is Restylane Shaype available in the US?
No, as of 22 August 2026. EU MDR approval on 11 August 2026 did not create a US PMA.
Sources
- U.S. Food and Drug Administration (FDA) PMA Database: Premarket Approval P110033/S047 — Juvéderm Voluma XC for Chin Augmentation (Approval Date: June 12, 2020). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033S047
- FDA Summary of Safety and Effectiveness Data (SSED): Juvéderm Voluma XC (P110033/S047B). Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S047B.pdf
- FDA Recently-Approved Devices: Restylane Defyne (P140029/S027) for Chin Retrusion (Approval Date: January 29, 2021). Available at: https://www.fda.gov/medical-devices/recently-approved-devices/restylane-defyne-p140029s027
- FDA PMA Database: Restylane Defyne Chin Augmentation (P140029/S027). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140029S027
- FDA PMA Database: Restylane Lyft with Lidocaine Chin Supplement (P040024/S142, Approval Date: November 4, 2025). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P040024S142
- FDA Summary of Safety and Effectiveness Data (SSED): Restylane Lyft with Lidocaine (P040024/S142). Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040024S142B.pdf
- FDA Recently-Approved Devices: Juvéderm Volux XC (P110033/S065) for Jawline Definition (Approval Date: July 29, 2022). Available at: https://www.fda.gov/medical-devices/recently-approved-devices/juvederm-volux-xc-p110033s065
- FDA PMA Database: Juvéderm Volux XC Jawline Indication (P110033/S065). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033S065
- ClinicalTrials.gov: VOLUMA-006 Chin Augmentation Pivotal Trial (NCT02833077). Available at: https://clinicaltrials.gov/study/NCT02833077
- ClinicalTrials.gov: Restylane Defyne Chin Retrusion Pivotal Trial (NCT03624816). Available at: https://clinicaltrials.gov/study/NCT03624816
- ClinicalTrials.gov: Restylane Lyft vs Voluma XC Chin Profile Study (NCT05777759). Available at: https://clinicaltrials.gov/study/NCT05777759
- PubMed Central (PMC): Using Injectable Fillers for Chin and Jawline Rejuvenation. PMC10296042. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10296042/
- Restylane USA Official Prescribing Information: Treatment Area — Chin. Galderma Laboratories, L.P. Available at: https://www.restylaneusa.com/treatment-area/chin
- Galderma Press Release: Galderma Receives European Union Approval for Restylane Shaype (August 11, 2026). Available at: https://www.galderma.com/news/galderma-receives-european-union-approval-restylaner-shaypetm-first-and-only-bone-mimicking
- FDA SSED: Restylane Defyne (P140029/S027B), including median chin injection volumes. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140029S027B.pdf
